Related Experiment Video

Updated: May 15, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Hepatitis C treatment - better outcomes through partner support

Fleur Chapman1, Alexandra McManus

  • 1Curtin Health Innovation Research Institute (CHIRI), Curtin University.

The Australasian Medical Journal
|January 5, 2013
PubMed

Insights

Supporting partners of hepatitis C patients is crucial. Greater assistance and social support for partners significantly improve treatment outcomes and family relationships during hepatitis C therapy.

Area of Science:

  • Hepatology
  • Public Health
  • Social Sciences

Background:

  • Hepatitis C affects 170 million globally, with 3-4 million new infections annually.
  • Approximately 1% of Australians have chronic hepatitis C, predominantly men.
  • Hepatitis C virus (HCV) infection poses a significant global health burden.

Purpose of the Study:

  • To explore the impact of hepatitis C treatment on patients' partners.
  • To identify the needs of female partners supporting men undergoing hepatitis C treatment.
  • To understand the role of social support in hepatitis C management.

Main Methods:

  • Qualitative study using in-depth interviews.
  • Recruited 8 partners of male hepatitis C patients and 3 service providers.
  • Focused on female partners' experiences during the male patient's treatment phase.

Main Results:

  • Partners recognized a need for increased support services.
  • Strong social support positively influenced hepatitis C treatment outcomes.
  • Social support was vital for maintaining family relationships during treatment.

Conclusions:

  • Formal partner support can enhance hepatitis C management.
  • Insights gained can improve outcomes beyond medical treatment.
  • Addressing partner needs is essential for holistic hepatitis C care.
Abstract

Keywords:
Caregivers/caringcoping and adaptationhepatitis C.partners

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...